FSSAI suspends Dior Pharmaceuticals’ nutraceutical manufacturing licence
India’s food regulator has suspended Dior Pharmaceuticals’ Punjab manufacturing licence with immediate effect after identifying critical GMP, hygiene, sanitation, storage and traceability gaps. Operations must remain halted until deficiencies are rectified and compliance is demonstrated.
What happened
FSSAI suspended Dior Pharmaceuticals' Punjab nutraceutical manufacturing licence with immediate effect after finding critical GMP, hygiene, safety-management,
Key facts
- FSS Act, 2006
- July 30, 2026
Why this matters
Any partnership, acquisition or supply arrangement involving Dior Pharmaceuticals warrants enhanced regulatory diligence given the identified manufacturing-control failures.
What to watch
- FSSAI inspection follow-up, corrective-action acceptance or licence reinstatement notice.
- Any product recall, stop-sale direction, adverse test result or consumer safety complaint.
- Length and breadth of stockouts across pharmacies, e-commerce and modern-trade channels.
- Retailer and marketplace delistings, search suppression, seller-account restrictions or demands for additional documentation.
- Evidence that the suspension affects only the Punjab facility versus Dior Pharmaceuticals' wider product portfolio or third-party manufacturing network.
- Competitor promotional activity, price changes and shelf-space gains in overlapping nutraceutical categories.
- Immediately halt production and quarantine finished goods, work-in-progress and relevant raw-material lots at the Punjab unit.
- Submit a time-bound corrective and preventive action plan to FSSAI, including independent GMP, hygiene, sanitation, storage and traceability audits.
- Review whether distributed inventory requires batch testing, withdrawal, recall or retailer notification.
- Communicate supply status and replacement plans to distributors, pharmacy chains, marketplaces and key retail accounts.
- Shift procurement or production to compliant approved facilities where legally permitted, while protecting quality consistency and regulatory documentation.
- Increase retailer-facing proof of compliance, including certificates of analysis, manufacturing-site credentials and batch traceability records.